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Background: Thyroid nodules with indeterminate cytological features on fine needle aspiration biopsy specimens
(FNABs) have a ~20% risk of thyroid cancer. BRAFV600E mutation and DNA methylation are useful markers to
distinguish malignant thyroid neoplasm from benign. The aim of this study was to determine whether combined
detection of BRAFV600E mutation and methylation markers on FNABs could improve the diagnostic accuracy of
thyroid cancer.
Methods: Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, FNABs from 79 and
38 patients with thyroid nodules in training and test groups, respectively, were analyzed for BRAFV600E mutation and
gene methylation.
Results: BRAFV600E mutation was found in 30/42 (71.4%) and 14/20 (70%) FNABs in training and test groups,
respectively. All BRAFV600E-positive samples were histologically diagnosed as papillary thyroid cancer (PTC) after
thyroidectomy. As expected, BRAF mutation was not found in all benign nodules. Moreover, we demonstrated that
the five genes, including CALCA, DAPK1, TIMP3, RAR-beta and RASSF1A, were aberrantly methylated in FNABs. Of
them, methylation level of DAPK1 in PTCs was significantly higher than that in benign samples (P <0.0001).
Conversely, methylation level of RASSF1A in PTCs was significantly lower than that in benign samples (P =0.003).
Notably, compared with BRAF mutation testing alone, combined detection of BRAF mutation and methylation
markers increased the diagnostic sensitivity and accuracy of PTC with excellent specificity.
Conclusion: Our data have demonstrated that combine analysis of BRAF mutation and DNA methylation markers
on FNABs may be a useful strategy to facilitate the diagnosis of malignant thyroid neoplasm, particularly PTC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/6080878071149177.
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Thyroid cancer is the most common endocrine malig-
nancy. The current rise in the incidence of thyroid can-
cer is mainly from an increased incidence in papillary
thyroid cancer (PTC) [1]. The initial presentation of thy-
roid cancer is usually a thyroid nodule, which is palpable
in approximately 5% of normal adults [1] and visualized
by sonography in one third or more of normal adults* Correspondence: phou@mail.xjtu.edu.cn; shibingy@126.com
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unless otherwise stated.[2,3]. Given that the prevalence of malignancy in solitary
thyroid nodules is only ~5% in adults [4,5], the preopera-
tive differentiation of benign from malignant thyroid nod-
ules is imperative. Fine needle aspiration biopsy (FNAB) is
the most reliable nonsurgical test for the diagnosis of thy-
roid cancer, with high sensitivity and specificity [6,7].
FNAB represents the “gold standard”, and is widely used
in the evaluation of thyroid nodules. However, ~20% of
FNABs are diagnosed as indeterminate cytological findings
that cannot distinguish cancerous from benign neoplasms
[8,9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of molecular markers play an important role in the diag-
nosis of thyroid nodules, such as BRAF and Ras muta-
tions, and RET/PTC rearrangements [10]. Of them, a
prominent oncogenic genetic event in PTC is BRAFV600E
mutation. This mutation occurs in the majority of cases
and results in the constitutively activated BRAF kinase
[11], which plays a fundamental role in thyroid tumorigen-
esis through driving Ras/Raf/MEK/ERK (MAPK) signaling
pathway [10,11]. Notably, BRAF mutation has consistently
been reported to be specific for PTC, whereas no benign
thyroid neoplasms or normal thyroid tissues have been
found to harbor this mutation. Thus, BRAF mutation has
the potential to be a specific molecular marker with rela-
tively high sensitivity for PTC diagnosis. In recent years,
accumulated evidences have demonstrated that BRAF mu-
tation detection on FNAB specimens (FNABs) enhances
the diagnostic value of cytology [12-14].
Epigenetic alterations, such as promoter hypermethyla-
tion, are one of the most common molecular events in hu-
man cancers, along with genetic alterations, ultimately
leading to carcinogenesis, including thyroid cancer [10,15].
Promoter hypermethylation is an important hallmark of
cancer cells and is responsible for transcriptional silencing
of tumor suppressor genes during tumorigenesis [16,17].
Aberrant DNA methylation usually occurs somatically in
cancer cells and can be released into blood circulation, it
may thus serve as a specific diagnostic blood test for cancer,
including thyroid cancer [18]. Hence it is not difficult to fol-
low that detection of methylated DNA on FNABs may po-
tentially be a useful diagnostic marker for thyroid cancer.
In this study, we detected BRAFV600E mutation and pro-
moter methylation of a panel of potential tumor suppressor
genes on FNABs using pyrosequnecing and quantitative
methylation-specific PCR (Q-MSP) approaches, and deter-
mined the diagnostic value of combined analysis of these
two molecular events on FNABs in the evaluation of thy-
roid nodules.
Methods
Patients and FNAB procedures
With the institutional review board approval and patient
consent, we recruited 117 study patients whom we were
able to obtain preoperative thyroid FNABs for BRAF mu-
tation and DNA methylation analysis at the First Affiliated
Hospital of Xi’an Jiaotong University School of Medicine
between August 2011 and December 2012. These patients
were chosen for this study because their thyroid nodule
was easily palpable for fine needle aspiration and they
were considered for thyroid surgery. To find appropriate
cut-off values that can distinguish between malignant and
benign nodules, 79 patients were classified into the train-
ing group, including 42 cases with PTC and 37 cases with
benign nodules. As an independent test group, FNABswere collected from 38 patients with thyroid nodule. Clini-
copathological data of the patients were summarized in
Table 1.
For the fine needle aspiration procedure, 2 or 3 passes
with 21-gauge needles were typically made to harvest
material for cytological and molecular analysis. Speci-
mens were collected in 500 μl normal saline solution in
a 1.5 ml EP tube. After centrifugation, the pellet was re-
suspended and washed twice with normal saline solu-
tion, and final pellet was used for DNA extraction.
DNA extraction
Genomic DNA was isolated using a protocol described
previously [19]. Briefly, the cells were incubated with 1%
sodium dodecyl sulfate (SDS) and 0.5 mg/ml proteinase
K at 48°C for 24–48 h. DNA was then isolated by using
standard phenol/chloroform protocol, and was dissolved
in distilled water and stored at −80°C until use.
Detection of BRAFV600E mutation by pyrosequencing assay
A 228-bp region of BRAF exon 15 spanning the hotspot
mutation site at codon 600 was amplified by PCR using
the forward and reverse primers 5′-biotin-CTT CAT AAT
GCT TGC TCT GAT AGG-3′ and 5′-GGC CAA AAA
TTT AAT CAG TGG AA-3′, respectively. The reaction
mixture contained, in a final volume of 25 μl, ~60 ng gen-
omic DNA, 1× PCR buffer, 1.5 mM MgCl2 , 0.2 mM of
each deoxynucleotide triphosphate (dATP, dCTP, dGTP,
and dTTP), 0.2 μM each primer (forward and reverse),
and 0.6 U platinum DNA Taq polymerase (Invitrogen Life
Technologies, Inc., MD). The PCR was performed with an
initial denaturation at 95°C for 5 min, followed by 35 cycles
of 95°C denaturation for 30 s, 58°C annealing for 30 s and
72°C elongation for 30 s. Quality of PCR products was de-
termined by gel electrophoresis. The PCR product was
immobilized onto streptavidin-coated sepharose beads
(GE Healthcare Bio-Sciences, PA) according to the in-
structions of the manufacturer. The bead/DNA complex
was washed and the supernatant was discarded. Sequen-
cing primer 5′-CCACTCCATCGAGATT-3′ was added
and annealed to the captured strand. Pyrosequencing
assay was then performed on a PyroMark Q24 system
using PyroMark Gold Q24 reagent (Qiagen).
Sodium bisulfite treatment and quantitative
methylation-specific PCR (Q-MSP)
Genomic DNA was subjected to bisulfite treatment as pre-
viously described [20]. Briefly, ~2 μg of DNA was dena-
tured by incubation with 0.3 M NaOH at 50°C for 20 min.
The denatured DNA was diluted in 500 μl of freshly pre-
pared solution of 10 mM hydroquinone and 3 M sodium
bisulfite, and incubated at 80°C for 3 h. The mixture was
then purified through a Wizard DNA Clean-Up System
(Promega Corp., Madison, WI) according to the instructions
Table 1 Clinicopathological characteristics of the patients with thyroid nodule
Characteristics No. of patients in training group (%) No. of patients in test group (%)
PTC (n =42) Benign (n =37) PTC (n =20) Benign (n =18)
Pathological subtypes
PTC 42 (100) – 20 (100) –
Nodular goiter – 26 (70.27) – 14 (77.78)
Thyroid adenoma – 11 (29.73) – 4 (22.23)
Gender
Male 12 (28.57) 9 (24.32) 3 (15.00) 2 (11.11)
Female 30 (71.43) 28 (75.68) 17 (85.00) 16 (88.89)
Age, years
Mean 45.16 40.31 41.33 40.20
SD 13.17 13.01 12.79 10.45
Tumor/nodule size (cm3)
≤ 3 32 (76.19) 18 (48.65) 14 (70.00) 7 (38.89)
3-5 9 (21.43) 14 (37.84) 6 (30.00) 9 (50.00)
≥5 1 (2.38) 5 (13.51) 0 2 (11.11)
Tumor invasion
Yes 14 (33.33) – 14 (70.00) –
No 28 (66.67) – 6 (30.00) –
Lymph node metastasis
Yes 22 (52.38) – 15 (75.00) –
No 20 (47.62) – 5 (25.00) –
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and resuspension in 100 μl of deionized H2O.
Q-MSP assay was performed as described previously
[20]. Briefly, quantitative PCR was carried out in a final
reaction mixture of 20 μl containing ~3 μl bisulfite-
treated DNA, 600 nM each primer, 200 nM TaqMan
probe, 5.5 mM MgCl2, 0.6 U platinum Taq polymerase,
and 200 μM each of deoxyguanosine triphosphate. The
specific primers and TaqMan probes for the target genes
and the internal reference gene β-actin were presented
in Table 2. After an initial denaturation step at 95°C for
2 min, 40 cylces of 15 sec at 95°C and 60 sec at 60°C for
annealing and extension were run on a CFX96 Thermal
Cycler Dice™ real-time PCR system (Bio-Rad Laborator-
ies, Inc., CA). Normal leukocyte DNA was methylated
in vitro with Sss I methylase (New England Biolabs,Table 2 Q-MSP primer and TaqMan probe sequences used in






β-actin TGGTGATGGAGGAGGTTTAGTAAGT 6FAM-ACCACCACCCAACBeverly, MA) to generate completely methylated DNA
as a positive control. Serial dilutions of completely meth-
ylated DNA were used to construct the standard curve.
The relative methylation level of each sample was calcu-
lated using the method described previously [21]. Each
sample was run in triplicate.
Statistical analysis
Non-parametric Wilcoxon’s Rank Sum test was used for
comparison of the differences in methylation levels be-
tween malignant and benign nodules because of the sig-
nificantly skewed distribution of the Q-MSP ratios. The
association of gene methylation with BRAF mutation was
determined using the Spearman’s correlation coefficient.
Diagnostic threshold analyses were performed using the
receiver operating characteristic (ROC) curves and thethis study
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performed using the SPSS statistical package (11.5, Chicago,
IL, USA). P values <0.05 were considered significant.
Results
Detection of BRAFV600E mutation on FNAB specimens
We used pyrosequencing assay to test BRAFV600E mutation
in a cohort of FNABs from 107 patients with thyroid nod-
ules, which consisted of training and test groups. The
former included 42 PTCs and 37 benign nodules. In these
PTCs, 30 of 42 (71.43%) cases were positive for BRAF mu-
tation. As expected, all benign nodules were negative for
BRAF mutation. The diagnostic sensitivity of BRAF muta-
tion was calculated as the number of PTCs with
BRAFV600E-positive divided by the total number of PTCs.
The specificity was calculated as the number of benign
cases with BRAFV600E-negative divided by the total number
of benign cases. Positive predictive value (PPV) was defined
as the number of PTCs with BRAFV600E-positive divided by
the total number of BRAFV600E-positive cases. Negative
predictive value (NPV) was defined as the number of be-
nign cases with BRAFV600E-negative divided by the total
number of BRAFV600E-negative cases. As shown in Table 3,
the sensitivity, specificity, PPV, NPV, and diagnostic accur-
acy of BRAF mutation detection on FNABs was 71.43%,
100%, 100%, 75.51%, and 71.43%, respectively.
Quantitative analysis of DNA methylation on FNAB
specimens
We performed Q-MSP assay on the five genes, CALCA,
RAR-beta, DAPK1, TIMP3, and RASSF1A on FNABs. The
differences in methylation levels of these markers between
PTCs and benign nodules were illustrated as scatter plots
in Figure 1. Among the five genes examined, statistical sig-
nificances were found in DAPK1 and RASSF1A genes.
Methylation level of DAPK1 in PTCs was significantly
higher than that in benign samples (P <0.0001). In con-
trast, RASSF1A gene showed lower methylation level in
PTCs than that in benign samples (P =0.003) (Figure 1).Table 3 Diagnostic values of BRAF mutation and various DNA
detection [percent (PTCs with BRAF mutation or methylation-
mutation or methylation-negative/total benign nodules, spec
total positive cases, PPV; benign nodules with BRAF mutation
Genes Cut-off values Sensitivity (%) Specific
BRAFV600E N/A 71.43 (30/42) 100 (3
CALCA 2.405 33.33 (14/42) 81.08 (
DAPK1 0.003 66.67 (28/42) 83.78 (
TIMP3 1.038 30.95 (13/42) 75.68 (
RAR-beta 1.606 30.95 (13/42) 75.68 (
RASSF1A 5.311 61.90 (26/42) 78.38 (
All five genes N/A 88.10 (37/42) 75.68 (
PPV, Positive predictive value; NPV, Negative predictive value.Given that all cases with BRAFV600E-positive were histo-
logically diagnosed as malignant thyroid neoplasm after
thyroidectomy, in order to further increase diagnostic sensi-
tivity, the cut-off values for each gene were calculated using
ROC curves to distinguish the cases with BRAFV600E-nega-
tive from benign nodules (Figure 2). Although AUCs for
DAPK1 (0.732) and RASSF1A (0.707) genes were better
than other genes, the diagnostic accuracy of these two
genes was still low (Table 3), suggesting that these DNA
methylation markers play a limited role in the diagnosis of
thyroid cancer.
Correction between BRAFV600E mutation and DNA
methylation
Given that several previous studies have shown an associ-
ation of BRAFV600E mutation with gene methylation in thy-
roid cancer [21-24], in this study, we also investigated the
relationship of DNA methylation levels with this mutation
found in these thyroid tumors. In our cohort of 79 thyroid
neoplasms, 20 of 40 PTCs and none of benign nodules har-
bored BRAF mutation. Of these five methylation markers
investigated, BRAF mutation was significantly associated
with DAPK1methylation (P =0.0009), as well as with an ab-
sence of RASSF1A methylation (P =0.026) by Wilcoxon test
analysis (Figure 3). The Spearman’s rank correlation ana-
lysis confirmed that both of these associations were signifi-
cant (P <0.05).
Combined detection of BRAFV600E mutation and
methylation markers for improving the diagnostic
accuracy of thyroid cancer
We next assessed the usefulness of combined detection of
BRAF mutation and methylation markers on FNABs in
the diagnosis of malignant thyroid neoplasm. We set up
appropriate cut-off values to distinguish malignant from
benign nodules in the training group, with more focus on
diagnostic accuracy for each combination. As shown in
Table 4, the specificity of each combination was all 100%.
The diagnostic sensitivity, ranging from 71.43 to 78.57%,methylation markers testing on FNAB specimens for PTC
positive/total PTCs, sensitivity; benign nodules with BRAF
ificity; PTCs with BRAF mutation or methylation-positive/
or methylation-negative/total negative nodules, NPV)]
ity (%) PPV (%) NPV (%) Accuracy (%)
7/37) 100 (30/30) 75.51 (37/49) 71.43
30/37) 66.67 (14/21) 51.72 (30/58) 14.41
31/37) 82.35 (28/34) 68.89 (31/45) 50.45
28/37) 59.09 (13/22) 49.12 (28/ 57) 6.63
28/37) 59.09 (13/22) 49.12 (28/57) 6.63
29/37) 76.47 (26/34) 62.22 (28/45) 40.28
28/37) 80.43 (37/46) 84.85 (28/33) 63.69
Figure 1 The overall methylation levels of the five genes in FNAB DNA samples from the patients with thyroid nodules. Q-MSP assay
was performed as described in Methods. The relative methylation level (on Y axis) is represented by ratios of candidate gene/β-actin (×100).
Horizontal lines indicate a 95% confidence interval for the sample mean. P values <0.05 were considered significant.
Zhang et al. Diagnostic Pathology 2014, 9:45 Page 5 of 9
http://www.diagnosticpathology.org/content/9/1/45was obtained for combining BRAFmutation with each indi-
vidual methylation marker. As compared with BRAF muta-
tion testing alone (71.43%), the sensitivity and accuracy of
combined analysis of each individual gene methylation and
BRAF mutation were not significantly improved (Table 4).
However, with these cut-off values of methylation, theFigure 2 Receiver operating characteristic (ROC) curves for these five
complete DNA methylation data were used for the analysis. The ROC curve
shown in the graph.overall diagnostic sensitivity and accuracy of the five genes
for thyroid cancer, when at least one of the five genes were
all positive, rose to 85.71%, with PPV and NPV of 100 and
86.05%, respectively. Subsequently, we performed BRAF
mutation detection and Q-MSP assay on FNABs from 38
patients with thyroid nodules (defined as test group), with agenes. All malignant and benign thyroid nodules for which there was
s plot sensitivity and 1-specificity. Areas under the curve (AUC) were
Figure 3 Association of BRAF mutation with methylation levels of these five genes in thyroid tumors. Shown were scatterplots of
methylation ratios in BRAF mutation positive (V600E) and negative (WT) neoplastic tumors (including benign and carcinomas). Horizontal lines
represent 95% confidence interval. P values <0.05 were considered significant.
Table 4 Diagnostic values of combined detection of BRAF mutation and various DNA methylation markers on FNAB
specimens for PTC detection [percent (PTCs with BRAF mutation or methylation-positive/total PTCs, sensitivity; benign
nodules with BRAF mutation or methylation-negative/total benign nodules, specificity; PTCs with BRAF mutation or
methylation-positive/total positive cases, PPV; benign nodules with BRAF mutation or methylation-negative/total
negative nodules, NPV)]
Cut-off values Training group (n =79)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
BRAFV600E N/A 71.43 (30/42) 100 (37/37) 100 (30/30) 75.51 (37/49) 71.43
CALCA + BRAFV600E 8.022 71.43 (30/42) 100 (37/37) 100 (30/30) 75.51 (37/49) 71.43
DAPK1 + BRAFV600E 0.64 78.57 (33/42) 100 (37/37) 100 (33/33) 80.43 (37/46) 78.57
TIMP3 + BRAFV600E 6.46 73.81 (31/42) 100 (37/37) 100 (31/31) 77.08 (37/48) 73.81
RAR-beta + BRAFV600E 11.21 73.81 (31/42) 100 (37/37) 100 (31/31) 77.08 (37/48) 73.81
RASSF1A + BRAFV600E 0.003 76.19 (32/42) 100 (37/37) 100 (32/32) 78.72 (37/47) 76.19
All five genes + BRAFV600E N/A 85.71 (36/42) 100 (37/37) 100 (36/36) 86.05 (37/43) 85.71
Cut-off values Test group (n =38)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
BRAFV600E N/A 70.00 (14/20) 100 (18/18) 100 (14/14) 75.00 (18/24) 70.00
CALCA + BRAFV600E 8.022 75.00 (15/20) 100 (18/18) 100 (15/15) 78.26 (18/23) 75.00
DAPK1 + BRAFV600E 0.64 80.00 (16/20) 94.44 (17/18) 94.12 (16/17) 80.95 (17/21) 74.44
TIMP3 + BRAFV600E 6.46 75.00 (15/20) 100 (18/18) 100 (15/15) 78.26 (18/23) 75.00
RAR-beta + BRAFV600E 11.21 75.00 (15/20) 100 (18/18) 100 (15/15) 78.26 (18/23) 75.00
RASSF1A + BRAFV600E 0.003 75.00 (15/20) 100 (18/18) 100 (15/15) 78.26 (18/23) 75.00
All five genes + BRAFV600E N/A 85.00 (17/20) 94.44 (17/18) 94.44 (17/18) 85.00 (17/20) 79.44
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tologically diagnosed as PTC after thyroidectomy. Other
samples were diagnosed as benign nodules. Also shown in
Table 4, in these PTCs, 14 of 20 (70%) cases were positive
for BRAFV600E mutation. Similarly, all benign nodules were
negative for BRAFV600E mutation. Using the same cut-off
values of methylation as for training group, the excellent
diagnostic specificity, ranging from 94.44 to 100%, was
found for each combination. As compared with BRAF mu-
tation testing alone, combined analysis of BRAF mutation
and methylation markers increased the diagnostic sensitiv-
ity, ranging from 5.00 to 15.00%, and the diagnostic accur-
acy, ranging from 4.44 to 9.44%, with the excellent
specificity, PPV and NPV (Table 4).
Discussion
Thyroid nodules are among the most common endo-
crine complaints in the world, which sometimes repre-
sents a significant diagnostic challenge in differentiating
malignant from benign lesions. Currently, morphological
diagnosis methods, such as immunohistochemistry and
cytology, play an important role in differentiating malig-
nant from benign nodules. For instance, depending on
the histomorphologic features of routine hematoxylin and
eosin (H&E), cytology of FNABs often provides a definitive
diagnosis and sound therapeutic guidance. However, a sub-
stantial number of cases cannot be diagnosed by this tech-
nique and many cases generate indeterminate results [9].
Nowadays, the role of molecular markers in cancer diag-
nosis and treatment has been established, including thy-
roid cancer [25,26]. For example, galectin-3, fibronectin-1,
CK-19, CK-903, CITED1, Ret oncoprotein, TG, Ki67, anti-
MAP kinase, p16, and the mesothelial cell surface protein
HBME-1 have been used as preoperative diagnostic
markers [27-32]. Unfortunately, none of them are specific
for thyroid malignancies.
In recent years, testing for the BRAFV600E mutation has
been extensively used to improve the diagnostic accuracy
of thyroid malignancy in nodules, because of the high spe-
cificity of this mutation for PTC [12-14,19,25,26,33].
BRAFV600E mutation, which is the most common onco-
genic genetic event found in thyroid cancer, particularly in
PTC, results in constitutive and oncogenic activation
of BRAF kinase in the MAPK signaling pathway [10].
Through activating MAPK pathway, the BRAF mutation
plays a fundamental role in the tumorigenesis of PTC and
predicts its poor clinical outcomes [10,11]. In this study,
we tested the role of BRAF mutation in the diagnosis of
malignant thyroid nodules. The data showed that the
prevalence of BRAF mutation was more than 70%, and
was highly specific for PTCs, as supported by our data that
all BRAFV600E-positive cases were histologically diagnosed
as PTC after thyroidectomy. These observations suggest
that molecular testing for BRAF mutation has animportant impact on the diagnosis of thyroid malignant
nodules, particularly PTC, as well as on decisions concern-
ing the extent of surgery, particularly in the cases with inde-
terminate fine-needle aspiration cytology. Generally, some
patients with indeterminate cytological findings undergo
total thyroidectomy, whereas others choose to receive hemi-
thyroidectomy. The patients in the latter group who prove
to have thyroid cancer are usually advised to undergo com-
pletion thyroidectomy. Thus, for thyroid nodule patients,
particularly the patients with indeterminate cytological find-
ings, preoperative evaluation of a specific molecular marker,
such as BRAF mutation, would be greatly helpful. In
addition, accumulated evidences have demonstrated that
the patients with BRAF mutation show frequent recurrence
and resistance to radioactive iodine therapy, BRAF muta-
tion may also be used as a prognostic factor [34,35]. BRAF
mutation testing would thus be a very informative and use-
ful tool in the management of thyroid nodules and cancers.
In addition to genetic factors, epigenetic events, such as
aberrant gene methylation, play a critical role in thyroid
tumorigenesis [15]. DNA methylation is one of major
mechanisms of inactivation of tumor-related genes, par-
ticularly tumor suppressor genes, in cancer cells. The ad-
vantages of gene methylation as a molecular marker for
the detection and diagnosis cancer in biopsy specimens
and non-invasive body fluids, such as serum, has led to
many studies of application in human cancers, including
thyroid cancer [18]. Similarly, we hypothesize that there is
potential value of gene methylation testing on FNABs as
diagnostic markers to distinguish malignant from benign
nodules. There are several reasons to support our hypoth-
esis. First, DNA methylation commonly occurs in thyroid
cancer [15]. Second, in generate, the amount of DNA from
cancer cells in FNABs is much greater than in serum sam-
ples. Third, DNA, unlike mRNA, is a stable molecule, offer-
ing the promise of greater test stability. Fourth, DNA
methylation can be quantitatively analyzed by Q-MSP assay
used in this study, which has become a well-established and
widely available technique [18,20,22,24]. In this study, we
have confirmed the measurability of FNAB methylation
markers and preliminarily defined the specificity and sensi-
tivity of a panel of methylation markers for evaluating thy-
roid nodules. Using these five genes, CALCA, RAR-beta,
DAPK1, TIMP3, and RASSF1A for differential diagnosis of
thyroid nodules with appropriate cut-off values, we were
able to identify positive gene methylation in 33.33-88.10% of
malignant nodules, but the diagnostic specificities were all
low, ranging from 75.68 to 83.78%. Although DAPK1 and
RASSF1A genes exhibited significantly different levels of
DNA methylation between malignant and benign nodules,
their diagnostic accuracy was still poor. These findings
suggest that quantitative detection of these methylation
markers on FNABs has serious limitations in the diagnosis
of thyroid cancer.
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previously reported inverse association with RASSF1A
methylation [22,24,36,37]. In addition, our data showed a
positive correlation between DAPK1methylation and BRAF
mutation. To our knowledge this is the first evidence indi-
cating a relationship between these two molecular alter-
ations in thyroid cancer. Given that both of BRAF mutation
and gene methylation play a key role in thyroid carcinogen-
esis and there is certain relationship between them, we pre-
sume that combined detection of these two molecular
events on FNABs may improve the diagnostic accuracy of
thyroid nodules. To this end, we performed BRAFmutation
and DNA methylation assays in training and test groups,
respectively, and demonstrated that, as compared with
BRAF mutation and DNA methylation testing each alone,
combined analysis of these two molecular events increased
the diagnostic sensitivity and accuracy, with excellent speci-
ficity (94.44-100%).
Conclusion
In summary, combined detection of BRAF mutation and
methylation markers on FNABs may be a useful strategy
in evaluation of thyroid nodules with indeterminate cyto-
logical findings. Importantly, such a combined analysis will
make preoperative risk and prognostic evaluation of ma-
lignant thyroid neoplasm more accurate and effective.
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